New developments in systemic lupus erythematosus

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)


In this review, the results of recent and ongoing clinical trials in patients with SLE are discussed. After many unsuccessful trials in the past decade, belimumab was the first biologic specifically designed for SLE that met its primary end point. At the same time, studies on the pathophysiology of SLE have further elucidated the pathways involved in the disease, which has led to the identification of new possible therapeutics and has encouraged the initiation of new trials. These new drugs include biologics that target B cells, T cells and type 1 interferons, and small molecules that inhibit kinases. Other therapeutics aim to restore immunological balance by restoring tolerance. Results from phase II and even phase III trials are promising and it is likely that some of the therapeutics discussed will receive approval in the following years. Hopefully, this will allow for more tailor-made medicine for SLE patients in the future.
Original languageEnglish
Pages (from-to)vi21-vi28
JournalRheumatology (Oxford, England)
Issue number6
Publication statusPublished - 24 Dec 2021


  • SLE
  • biologic therapies
  • targeted therapies
  • therapy

Cite this